Sartorius

This webinar will cover the advantages of a fully automated in-line lysis system with a closed single-use loop for process development. In addition to state-of-the-art mixing control, it can be configured to automatically and continuously process up to 10–50 kg of resuspended E. coli cells every 8 hours.

https://www.biopharminternational.com/bp_w/alkaline-lysis

Generally, methods applied for the isolation of plasmid DNA involve a cell lysis step with the addition of a strong base (alkaline lysis), neutralization, and precipitation to recover the target pDNA in solution from precipitated contaminating cell components (genomic DNA, proteins, and protein-nucleic acid complexes). Uncontrolled use of an alkaline solution will degrade target pDNA, which is also sensitive to mechanical stress. Furthermore, highly viscous solutions may cause local heterogeneities or require extensive mixing, both potentially degrading the target pDNA. This webinar will present a fully automated in-line lysis system with a closed single-use loop for process development up to a pilot scale in the GMP environment. With a state-of-the-art mixing control, it can be configured to automatically and continuously process up to 10–50 kg of resuspended cells per workday depending on the configuration.

Understand challenges associated with alkaline lysis at the pilot scale.

See the advantages presented by the Sartorius in-line lysis machine compared with batch lysis.

Learn about at-line in-process control strategies for challenging crude lysis samples.


Product Manager
Sartorius BIA Separations

 continued as a team leader in Knauf insulation, where he managed the analytical support and material development in the EMEA region. Matevz joined Sartorius BIA Separations in 2021 as a project manager and two years later became fully active in in-line lysis machine development and GMP implementation. He is also an acrobatic basketball performer, never found in his comfort zone.


Webcasts

Webinar Date/Time: Tue, Jun 11, 2024 10:00 AM EDT




Sartorius In-Line Lysis System: The Easiest Alternative to Batch Alkaline Lysis

Articles

The Cubis®️ II balance, equipped with a pharma package, provides technical features for regulatory compliance in pharmaceutical quality control. Complete compliance requires extra procedural controls and data storage systems. Our checklist highlights key regulatory details and shows how Cubis®️ II facilitates full pharma compliance.

21 CFR Part 11 Compliance Checklist

Pharma companies must comply with pharmacopeia regulations, like the USP for the US and Ph.Eur. for Europe, to market drugs. The USP has long had a chapter on lab balances, while the Ph.Eur. introduced a similar mandatory chapter in January 2022. Our infographic compares lab balance rules in both pharmacopeias, noting their differences.

Laboratory Balances in the Pharmaceutical Industry (Dec 2023)

The European Pharmacopoeia's new Chapter 2.1.7 on analytical balances was published on July 1, 2021, and became mandatory for pharma companies in Europe from January 1, 2022. It outlines calibration and performance standards for balances. Our white paper compares this with USP Chapters <41> and <1251>.

Use of Laboratory Balances in the Pharmaceutical Industry

The European Pharmacopoeia's new section 2.1.7 on analytical balances was released in July 2021 and enforced from January 1, 2022. It's a mandatory standard for pharmaceuticals in Europe. Download our FAQ for compliance tips and how our Cubis® II lab balance can help.

Pharmacopoeia Compliance Guide: Chapter 2.1.7 Ph.Eur. "Balances for analytical purposes"

Review testing requirements for lab balances in the pharmaceutical industry described in the relevant pharmacopoeias and the associated certificates offered by Sartorius.